The present invention relates to compounds having the formula, ##STR00001## and pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, or pyrazinyl ring; R.sub.2 is alkyl or an amino group as defined herein; and Z is optionally-substituted oxadiazolyl or --C(.dbd.O)NR.sub.6, wherein R.sub.6 is lower alkyl or cyclopropyl. The compounds are surprisingly advantageous in preparing phar...

Novel pyrazolylbiphenylcarboxamides of the formula (I) ##STR00001## in which R.sup.1, R.sup.2, X, m, Y and n are each as defined in the description, a plurality of processes for preparing these substances and their use for controlling undesirable microorganisms, and also novel intermediates and their preparation.

A compound of the formula (I): ##STR1## wherein: R.sup.1 is chlorine, difluoromethyl, trifluoromethyl or cyano; and R.sup.2 is a group having the formula: ##STR2## wherein: X is halogen, cyano, nitro or amino; Y.sup.1 is lower alkyl or lower alkoxy; and Z is halogen; or a pharmaceutically acceptable salt thereof.

Pollen formation in cereal grain plants is inhibited by application of a 4-carboxy(or derivative)-1-aryl-5-pyrazolecarboxamide. Production of hybrid seed is facilitated by use of the compounds.

The present invention relates to compounds of the formula: ##STR1## These compounds are useful in pharmaceuticals in which cannabis is known to be involved.

A process for producing N-monosubstituted acrylamides in high yields without forming by-products. The process comprises preparing a .beta.-dialkylamino-(methyl)propionic ester by the reaction of a (meth)-acrylic ester with a specified dialkylamine, converting the formed ester into an N-monosubstituted .beta.-dialkylamino(methyl)propionamide by the reaction thereof with a primary amine in the presence of sodium methoxide, and thermally decomposing the amide under a reduced pressure.

Compounds of Formula I are disclosed which inhibit hepatitis C NS5B RNA-dependent RNA polymerase and are useful for treating hepatitis C. Compositions and methods of using these compounds are also disclosed ##STR00001##

1-Phenylpyrazole compounds of the formula (1): ##STR1## which is exemplified by 5-amino-1-(3-cyano-4-isobutoxyphenyl)pyrazole-4-carboxylic acid, an optical isomer thereof and a pharmaceutically acceptable salt thereof. These compounds have a xanthine oxidase inhibitory activity and are useful as therapeutic agents for diseases such as hyperuricacidemia and gout.

A new process for the preparation of a known 1,3-dimethyl-5-fluoro-pyrazole-4-carboxanilide of the formula ##STR1## in which Ar represents optionally substituted phenyl, which process comprises a) reacting in a first stage, 1,3-dimethyl-5-chloro-pyrazole-4-carbonyl chloride with a fluoride, if appropriate in the presence of a diluent, and b) reacting in a second stage, the 1,3-dimethyl-5-fluoro-pyrazole-4-carbonyl fluoride obtained in this reaction with an aniline of the formula in which Ar has ...

The present invention relates to new pyrazole derivatives possessing an amide group substituted with an amino acid or one of its derivatives at position 3 and variously substituted in positions 1, 2, 4 or 5 of the pyrazole ring, to a process for preparing these and to pharmaceutical compositions containing the said pyrazole derivatives as an active ingredient.